<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="condition" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1002" relname="same_unit">The objective of this paper</segment>
<segment id="3" parent="1005" relname="span">was using the Essential Medicines List for children by the World Health Organization</segment>
<segment id="4" parent="3" relname="elaboration">( WHO )</segment>
<segment id="5" parent="1006" relname="span">to create a provisional pediatric biopharmaceutics classification system</segment>
<segment id="6" parent="5" relname="elaboration">( pBCS )</segment>
<segment id="7" parent="1007" relname="joint">for oral drugs</segment>
<segment id="8" parent="1008" relname="span">and to compare our results with the BCS for adults</segment>
<segment id="9" parent="8" relname="elaboration">( aBCS ) .</segment>
<segment id="10" parent="1009" relname="joint">Since 2007 , the WHO has provided the WHO Model List of Essential Medicines for Children ;</segment>
<segment id="11" parent="1010" relname="span">a core drug list for a basic health-care system .</segment>
<segment id="12" parent="1011" relname="joint">This resource list considers the safest , efficacious and cost-effective drugs for priority pathologies in pediatrics up to 12 years old .</segment>
<segment id="13" parent="1013" relname="preparation">All immediate release oral drugs from the sixth edition of this list were selected for this work .</segment>
<segment id="14" parent="1014" relname="span">The need for and importance</segment>
<segment id="15" parent="14" relname="elaboration">of developing appropriate , safe and effective medicines for pediatrics have now been recognized .</segment>
<segment id="16" parent="1016" relname="preparation">Pediatrics have long been considered as a therapeutically disregarded group .</segment>
<segment id="17" parent="1019" relname="span">This fact lies in the therapeutic gap</segment>
<segment id="18" parent="17" relname="elaboration">that originates from formulation development</segment>
<segment id="19" parent="1019" relname="elaboration">( mainly focused on adults ) ,</segment>
<segment id="20" parent="1017" relname="same_unit">low availability of commercial pediatric drugs for pediatric use and physiological and anatomical differences relative to the adult population .</segment>
<segment id="21" parent="1021" relname="span">In younger pediatrics , neonates and infants , the therapeutic-risk benefits</segment>
<segment id="22" parent="21" relname="elaboration">associated with drug treatment may be different from those in adults .</segment>
<segment id="23" parent="1024" relname="span">Developmental physiological differences</segment>
<segment id="24" parent="23" relname="elaboration">( as the composition of gastrointestinal fluids and the presence or activity of intestinal drug metabolizing enzymes and efflux transporters )</segment>
<segment id="25" parent="1023" relname="same_unit">can markedly alter the bioavailability of drugs .</segment>
<segment id="26" parent="1026" relname="span">Age-related changes in the characteristics of luminal fluids such as pH may lead to changes in drug solubility and , therefore , in absorption</segment>
<segment id="27" parent="26" relname="circumstance">since only the dissolved drug would be available for absorption .</segment>
<segment id="28" parent="29" relname="concession">Since fluctuations in pH may influence ionizable drugs and the relative amount of unionized available drug ,</segment>
<segment id="29" parent="1028" relname="span">there could be changes in absorption during maturation .</segment>
<segment id="30" parent="1030" relname="joint">The gastric pH of the newborn is approximately neutral ,</segment>
<segment id="31" parent="1031" relname="sequence">and within the first 48 h of life , the gastrointestinal pH decreases to adult values</segment>
<segment id="32" parent="1031" relname="sequence">and then for the first month increases back to values close to neutrality .</segment>
<segment id="33" parent="1033" relname="span">After the first month , gastric pH decreases progressively to reach similar values as in adults by two years of age .</segment>
<segment id="34" parent="1035" relname="span">On the other hand , another determinant of bioavailability is ontogenic changes in the expression of drug metabolizing enzymes and transporters ,</segment>
<segment id="35" parent="1036" relname="joint">which would mark the first pass effect</segment>
<segment id="36" parent="1036" relname="joint">and consequently would change the oral absorbed fraction .</segment>
<segment id="37" parent="1037" relname="span">For example , the CYP3A4 isoenzyme increases expression and activity with age .</segment>
<segment id="38" parent="1039" relname="joint">CYP3A4 is practically undetectable in neonates ,</segment>
<segment id="39" parent="1040" relname="span">and its expression increases with age ,</segment>
<segment id="40" parent="39" relname="elaboration">reaching a maximum level at two years of age .</segment>
<segment id="41" parent="1041" relname="span">Likewise , in these age groups , there is immature intestinal activity of alkaline phosphatase , glucuronidation enzymes and carboxylesterase-2 .</segment>
<segment id="42" parent="1042" relname="span">Conversely , there are no differences in p-glycoprotein expression , the most studied intestinal efflux transporter from the earliest stages of life to adults .</segment>
<segment id="43" parent="1044" relname="span">Many drugs are formulated as pharmaceutical forms</segment>
<segment id="44" parent="43" relname="elaboration">that are often not appropriate for pediatrics , such as tablets or capsules .</segment>
<segment id="45" parent="1047" relname="span">Children need different oral dosage formulations from adults</segment>
<segment id="46" parent="45" relname="elaboration">mainly</segment>
<segment id="47" parent="1046" relname="same_unit">due to their developmental capabilities in swallowing ability , palatability and dosage requirements .</segment>
<segment id="48" parent="1048" relname="span">Especially in pediatrics , palatability is closely related to acceptance and adherence .</segment>
<segment id="49" parent="48" relname="elaboration">Consequently , bitterness , trigeminal irritation and perceptible malodors must be minimized .</segment>
<segment id="50" parent="1050" relname="span">The increasing need for age-related medicines in pediatrics could be met by extemporaneous formulations .</segment>
<segment id="51" parent="1052" relname="span">The compounding of an extemporaneous formula is not allowed</segment>
<segment id="52" parent="1054" relname="span">if an authorized commercial pharmaceutical product</segment>
<segment id="53" parent="52" relname="elaboration">( adequate for a particular age group )</segment>
<segment id="54" parent="1053" relname="same_unit">exists ,</segment>
<segment id="55" parent="1055" relname="span">but the reality in the clinical setting is that for some age groups ,</segment>
<segment id="56" parent="1056" relname="span">that is not the case ,</segment>
<segment id="57" parent="56" relname="circumstance">while extemporaneous formulation is still used as the only alternative to the therapeutic need .</segment>
<segment id="58" parent="1059" relname="concession">Although solid products have higher stability than liquid formulations ,</segment>
<segment id="59" parent="1060" relname="span">this practice can solve the problem</segment>
<segment id="60" parent="59" relname="elaboration">of swallowing capability and dose adjustments ,</segment>
<segment id="61" parent="1061" relname="span">but these manufactured preparations can be a risk to safety , efficacy and quality ,</segment>
<segment id="62" parent="1062" relname="span">because there is little or no information</segment>
<segment id="63" parent="62" relname="purpose">for compatibility between the original medicine and additional excipients or their effect in children .</segment>
<segment id="64" parent="1065" relname="span">The excipients</segment>
<segment id="65" parent="64" relname="elaboration">used in formulations</segment>
<segment id="66" parent="1066" relname="span">designed for children should be appropriate for each age group</segment>
<segment id="67" parent="1067" relname="same_unit">because ,</segment>
<segment id="68" parent="1069" relname="circumstance">as is known ,</segment>
<segment id="69" parent="1069" relname="joint">these are not inert substances</segment>
<segment id="70" parent="1069" relname="joint">and cannot be supposed to have the same effects in pediatrics as in adults .</segment>
<segment id="71" parent="1071" relname="span">The most common example is early stage children</segment>
<segment id="72" parent="71" relname="elaboration">who are not able to metabolize or eliminate them as adults .</segment>
<segment id="73" parent="1070" relname="joint">The ideal situation in the development of pediatric formulations is the minimal use of added excipients , both in number and quantity .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="multinuc" parent="1009" relname="background"/>
<group id="1003" type="span" parent="1002" relname="same_unit"/>
<group id="1004" type="span" parent="1003" relname="span"/>
<group id="1005" type="span" parent="1004" relname="span"/>
<group id="1006" type="span" parent="1005" relname="purpose"/>
<group id="1007" type="multinuc" parent="1004" relname="purpose"/>
<group id="1008" type="span" parent="1007" relname="joint"/>
<group id="1009" type="multinuc" parent="1001" relname="span"/>
<group id="1010" type="span" parent="1009" relname="joint"/>
<group id="1011" type="multinuc" parent="11" relname="elaboration"/>
<group id="1012" type="span" parent="1011" relname="joint"/>
<group id="1013" type="multinuc" parent="1012" relname="span"/>
<group id="1014" type="span" parent="1013" relname="joint"/>
<group id="1015" type="span" parent="1013" relname="joint"/>
<group id="1016" type="multinuc" parent="1015" relname="span"/>
<group id="1017" type="multinuc" parent="1016" relname="joint"/>
<group id="1018" type="span" parent="1017" relname="same_unit"/>
<group id="1019" type="span" parent="1018" relname="span"/>
<group id="1020" type="multinuc" parent="1016" relname="joint"/>
<group id="1021" type="span" parent="1020" relname="joint"/>
<group id="1022" type="multinuc" parent="1020" relname="joint"/>
<group id="1023" type="multinuc" parent="1022" relname="joint"/>
<group id="1024" type="span" parent="1023" relname="same_unit"/>
<group id="1025" type="multinuc" parent="1022" relname="joint"/>
<group id="1026" type="span" parent="1025" relname="joint"/>
<group id="1027" type="multinuc" parent="1025" relname="joint"/>
<group id="1028" type="span" parent="1027" relname="joint"/>
<group id="1029" type="multinuc" parent="1027" relname="joint"/>
<group id="1030" type="multinuc" parent="1029" relname="sequence"/>
<group id="1031" type="multinuc" parent="1030" relname="joint"/>
<group id="1032" type="multinuc" parent="1029" relname="sequence"/>
<group id="1033" type="span" parent="1032" relname="sequence"/>
<group id="1034" type="span" parent="33" relname="elaboration"/>
<group id="1035" type="span" parent="1034" relname="span"/>
<group id="1036" type="multinuc" parent="34" relname="elaboration"/>
<group id="1037" type="span" parent="1035" relname="elaboration"/>
<group id="1038" type="multinuc" parent="37" relname="elaboration"/>
<group id="1039" type="multinuc" parent="1038" relname="joint"/>
<group id="1040" type="span" parent="1039" relname="joint"/>
<group id="1041" type="span" parent="1038" relname="joint"/>
<group id="1042" type="span" parent="41" relname="elaboration"/>
<group id="1043" type="span" parent="42" relname="elaboration"/>
<group id="1044" type="span" parent="1043" relname="span"/>
<group id="1045" type="span" parent="1044" relname="elaboration"/>
<group id="1046" type="multinuc" parent="1045" relname="span"/>
<group id="1047" type="span" parent="1046" relname="same_unit"/>
<group id="1048" type="span" parent="1046" relname="elaboration"/>
<group id="1049" type="multinuc" parent="1032" relname="sequence"/>
<group id="1050" type="span" parent="1049" relname="joint"/>
<group id="1051" type="multinuc" parent="50" relname="elaboration"/>
<group id="1052" type="span" parent="1051" relname="contrast"/>
<group id="1053" type="multinuc" parent="51" relname="condition"/>
<group id="1054" type="span" parent="1053" relname="same_unit"/>
<group id="1055" type="span" parent="1051" relname="contrast"/>
<group id="1056" type="span" parent="55" relname="elaboration"/>
<group id="1057" type="span" parent="1049" relname="joint"/>
<group id="1058" type="span" parent="1057" relname="span"/>
<group id="1059" type="multinuc" parent="1058" relname="span"/>
<group id="1060" type="span" parent="1059" relname="contrast"/>
<group id="1061" type="span" parent="1059" relname="contrast"/>
<group id="1062" type="span" parent="61" relname="cause"/>
<group id="1063" type="multinuc" parent="1058" relname="elaboration"/>
<group id="1064" type="span" parent="1063" relname="joint"/>
<group id="1065" type="span" parent="1064" relname="span"/>
<group id="1066" type="span" parent="1065" relname="elaboration"/>
<group id="1067" type="multinuc" parent="66" relname="cause"/>
<group id="1068" type="span" parent="1067" relname="same_unit"/>
<group id="1069" type="multinuc" parent="1068" relname="span"/>
<group id="1070" type="multinuc" parent="1063" relname="joint"/>
<group id="1071" type="span" parent="1070" relname="joint"/>
	</body>
</rst>
